|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Mental Health (NIMH) |
|---|---|
| Information provided by: | National Institute of Mental Health (NIMH) |
| ClinicalTrials.gov Identifier: | NCT00712699 |
Purpose
This study will evaluate the safety and effectiveness of extended release mixed amphetamine salts in treating preschool children with attention deficit hyperactivity disorder.
| Condition | Intervention |
|---|---|
|
Attention Deficit Disorder With Hyperactivity |
Drug: Extended release mixed amphetamine salts Drug: Placebo |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Crossover Assignment, Safety/Efficacy Study |
| Official Title: | Placebo vs. Extended Release Stimulant Crossover Trial in Preschoolers With ADHD |
| Estimated Enrollment: | 30 |
| Study Start Date: | June 2008 |
| Estimated Study Completion Date: | August 2009 |
| Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
Participants will first receive treatment with extended release mixed amphetamine salts for 3 weeks and then placebo for 3 weeks.
|
Drug: Extended release mixed amphetamine salts
Participants will take a daily 5-mg dose for the first week, a daily 10-mg dose for the second week, and a daily 15-mg maximum dose by the third week.
Drug: Placebo
Participants will take a daily 5-mg dose for the first week, a daily 10-mg dose for the second week, and a daily 15-mg maximum dose by the third week.
|
|
2: Experimental
Participants will first receive treatment with placebo for 3 weeks and then extended release mixed amphetamine salts for 3 weeks.
|
Drug: Extended release mixed amphetamine salts
Participants will take a daily 5-mg dose for the first week, a daily 10-mg dose for the second week, and a daily 15-mg maximum dose by the third week.
Drug: Placebo
Participants will take a daily 5-mg dose for the first week, a daily 10-mg dose for the second week, and a daily 15-mg maximum dose by the third week.
|
Attention deficit hyperactivity disorder (ADHD) is a common developmental disorder that affects between 4% and 12% of school-aged children. Children with ADHD often show symptoms of hyperactivity, inattention, inability to sit still, trouble listening, excessive talking, and aggression. ADHD is generally not diagnosed and treated in children less than 6 years old because some symptoms of ADHD are difficult to distinguish from normal behaviors of preschool-aged children. However, some preschool children who exhibit symptoms indicative of ADHD and who have been carefully diagnosed by a health professional may benefit from early treatment to lower risk for functional impairment later in childhood. Currently, environmental changes, parent effectiveness training, and behavior therapy are the commonly used treatments for preschoolers with ADHD symptoms, but not all preschoolers respond well to such behavioral interventions. These children may benefit from medication treatment; however, the safety and effectiveness of ADHD medications in treating preschool-aged children is not well known. Extended release mixed amphetamine salts (XR-MAS), a stimulant medication, is a commonly prescribed and approved medication for treating ADHD in children 6 years and older. Further study is needed to determine how XR-MAS affects preschool-aged children with ADHD symptoms. This study will compare the safety and effectiveness of XR-MAS versus placebo in treating preschool children with ADHD.
Participation in this study will last 6 weeks. All participants will first undergo rigorous psychiatric assessments to confirm their diagnosis of ADHD. Eligible participants will then be assigned randomly to receive treatment with either XR-MAS then placebo or placebo then XR-MAS. Participants will take their assigned XR-MAS or placebo medications for 3 weeks and then cross over to the other medication for an additional 3 weeks of treatment. Rating scale scores will be collected weekly from parents and teachers to assess symptom response and measures of safety.
Eligibility| Ages Eligible for Study: | 36 Months to 66 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: John H. Fanton, MD | 413-794-7492 | john.fanton@bhs.org |
| Contact: Bruce D. Waslick, MD | 413-794-7035 ext 2 | bruce.waslick@bhs.org |
| United States, Massachusetts | |
| Baystate Medical Center | Recruiting |
| Springfield, Massachusetts, United States, 01199 | |
| Principal Investigator: John H. Fanton, MD | |
| Principal Investigator: | John H. Fanton, MD | Baystate Medical Center |
More Information
| Responsible Party: | Baystate Medical Center ( John H. Fanton, MD ) |
| Study ID Numbers: | F32 MH078388, DDTR BK-TKFND |
| Study First Received: | July 8, 2008 |
| Last Updated: | July 15, 2008 |
| ClinicalTrials.gov Identifier: | NCT00712699 |
| Health Authority: | United States: Federal Government |
|
Preschool Children ADHD Medication |
Controlled Study Placebo Mixed Amphetamine Salts |
|
Signs and Symptoms Methamphetamine Dopamine Attention Deficit Disorder with Hyperactivity Adderall Mental Disorders |
Mental Disorders Diagnosed in Childhood Neurologic Manifestations Attention Deficit and Disruptive Behavior Disorders Hyperkinesis Amphetamine Dyskinesias |
|
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Adrenergic Agents Molecular Mechanisms of Pharmacological Action Adrenergic Uptake Inhibitors Sympathomimetics Nervous System Diseases |
Physiological Effects of Drugs Central Nervous System Stimulants Pharmacologic Actions Pathologic Processes Autonomic Agents Therapeutic Uses Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |
